Emergent Announces Resolution of New York Attorney General Investigation
Emergent BioSolutions has reached an agreement with the Office of the Attorney General of the State of New York (OAG) to resolve its investigation related to legacy claims regarding the company’s approval of an executive trading plan in November 2020.
Under the terms of the agreement, Emergent has agreed to pay $900,000 to the State of New York and implement enhancements to its Insider Trading Policy. In addition, Emergent will provide reporting to the OAG for a period of three years regarding trading plans adopted, modified, or terminated by senior management and board members.
Emergent remains committed to the highest standards of quality, ethics and compliance, and has taken significant action to improve transparency and integrity in all aspects of its operations.
About Emergent BioSolutions:
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com